PPT-From LP2 to 2S-LP2: discovery of a biased dual-target mu/delta opioid receptor agonist

Rita Turnaturi 1 Carmela Parenti 2 Girolamo Calo 3 Santina Chiechio 2 Agostino Marrazzo 1 and Lorella Pasquinucci 1 1 Department of Drug Sciences Medicinal Chemistry Section University of Catania Catania Italy . June 21, 2016 | Governor’s Planning Meeting. Reka Danko, M.D. . Chief Medical Officer|Director of MAT program, Northern Nevada HOPES. Hospitalist, Saint Mary’s Medical Center|Rosewood Rehabilitation. Andrew Sonderman, MD. Prescription Drug Abuse. Newest . problem in the . field. Patients . believe . that they are “medications” and . do not . look at them as . drugs. Pharmaceutical companies make a fortune selling a “pill for every . Pain management. By Roshni Guerry, MD. Supportive and Palliative Care Inpatient Medical Director. Objectives. Describe four classifications of opioids. . and their preferred indications. List which opioids are preferred for renal and liver patients. Residency Program Director, SUNY Stony Brook Dept of PM&R . Opioid Misuse/ Abuse is a Major Public Health Problem. . Improper use of opiates can result in serious adverse events including overdose and death . Daniel P. Edney MD FACP. Objectives. Review common complications. Review CDC treatment guidelines. Review basic exit strategies. Common Complications. Tolerance. Dependency. Opioid Induced Hyperalgesia. Pain. . Pain. persists Pain persists. or increases or increases. 1. . Non. -. opioid. ± adjuvant. 2. Weak . opioid. ± non-. opioid. ± adjuvant. 3. Strong . opioid. Copyright 2019. Jason McLott. All Rights Reserved. . Disclosure Statement. I have no financial relationships with any commercial interest related to the content of this activity. I will discuss the off label use of many medications. an . unpleasant sensation that can be either acute or chronic and is a consequence of complex neurochemical processes in the peripheral and central nervous systems (. CNS. Alleviation . of pain depends on the . MD., DA., DNB, Dip. Diab., PhD (physiology). Dip. Software based statistics- . IDRA, CUGRA . What are they ? . Minor changes in the structure of an opioid agonist. . convert the drug into an opioid antagonist at one or more of the opioid receptor sites . Tim Furnish, MD. Clinical Professor. UC San Diego Health. August . 2023. Disclosures. Fellowship Educational Grants: . Medtronic, Abbott, Boston Scientific, Nevro. Buprenorphine. Buprenorphine. FDA Indications, uses, and legal distinctions. Opioid.   The class of drugs that includes opiates, . opiopeptins. , and all synthetic and . semisynthetic. drugs that mimic the actions of the opiates . Opioid. peptides.   Endogenous peptides that act on . Professor, Associate Chair, and Director of Substance Abuse Research Division. Dept. of Psychiatry and Behavioral Neurosciences; and Dept. of Pharmacy Practice. Wayne State University, Detroit, MI, USA. This . project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under contract number HHSH250201600015C. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government.. Nathan Bryant, PharmD. Pain Management Pharmacist. Presbyterian Healthcare Services. Disclosures. I have no financial relationships to disclose related to any content within this presentation.. Content includes discussion of .